Short answer
Absci Corp (ABSI) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $215,000 (down 81.8% year over year) with net income of −$30M.
Q1 2026 key financials · XBRL
- Revenue
- $215,000
- −81.8% YoY
- Net income
- −$30M
- −12.3% YoY
- Operating margin
- -14347.0%
- EPS (diluted)
- −$0.19
- +9.5% YoY
Source: XBRL data from the Absci Corp (ABSI) Q1 2026 10-Q on SEC EDGAR. USD.
Absci Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0.2M, down 82% YoY from $1.2M, reflecting milestone timing and partnered-program mix
- Operating loss $30.8M vs $27.7M YoY; net loss $29.6M vs $26.3M
- R&D expenses $19.3M, up 18% YoY; ABS-201 development costs increased $1.6M
- Cash, equivalents and marketable securities $125.7M; operating cash use $26.3M vs $21.8M YoY
- ABS-201 interim proof-of-concept data expected second half 2026; endometriosis Phase 2 anticipated fourth quarter 2026
Risk Factors
- Partnering-model risk: no partner had licensed related intellectual property for clinical or commercial use as of May 7, 2026
- Liquidity risk: $125.7 million in cash, cash equivalents and marketable securities as of March 31, 2026
- Regulatory risk: reported FDA staffing cuts could delay IND reviews, guidance, or enforcement
- Clinical risk: ABS-101 and ABS-201 only recently entered Phase 1 trials, while other programs remain preclinical
- Revenue concentration risk: all three-month March 2026 revenue came from partnered drug-creation activities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Absci Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.